Synthetic Biologics Inc (NYSEAMERICAN:SYN) major shareholder Randal J. Kirk sold 150,565 shares of Synthetic Biologics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $0.66, for a total transaction of $99,372.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
NYSEAMERICAN SYN traded down $0.02 during trading on Friday, reaching $0.62. The company’s stock had a trading volume of 100,900 shares, compared to its average volume of 312,676. Synthetic Biologics Inc has a 1-year low of $0.51 and a 1-year high of $10.43.
Synthetic Biologics (NYSEAMERICAN:SYN) last posted its earnings results on Wednesday, February 27th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.95).
Separately, Zacks Investment Research upgraded shares of Synthetic Biologics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 29th.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/26/synthetic-biologics-inc-syn-major-shareholder-randal-j-kirk-sells-150565-shares.html.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.
Featured Story: Why investors pay attention to retained earnings
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.